DLL3 and small cell lung carcinoma: The researchers specifically proposed that combining Rova-T with anti-PD(L)1 could be advantageous for patients by activating multiple pathways synergistically, thus enhancing the effects of immune system targeting and directly attacking SCLC tumor cells that express DLL3.